Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
Phillip Pymm(The University of Melbourne), Nicholas A. Gherardin(Peter Doherty Institute), Ebene R. Haycroft(The University of Melbourne), Samantha L. Grimley(The University of Melbourne), Rebecca Seneviratna(The University of Melbourne), Wai‐Hong Tham(The University of Melbourne), Alisa Glukhova(The University of Melbourne), Damian F. J. Purcell(The University of Melbourne), Lin‐Fa Wang(Beijing Institute of Technology), Stephen J. Kent(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Samuel J. Redmond(The University of Melbourne), Olan Dolezal(Commonwealth Scientific and Industrial Research Organisation), Dale I. Godfrey(Peter Doherty Institute), Andrew Leis(Walter and Eliza Hall Institute of Medical Research), Kanta Subbarao(Peter Doherty Institute), Francesca L. Mordant(The University of Melbourne), James P. Cooney(The University of Melbourne), Amy W. Chung(The University of Melbourne), Ester López(The University of Melbourne), Adam P. Uldrich(Peter Doherty Institute), Adam K. Wheatley(The University of Melbourne), Kathryn C. Davidson(Australian Regenerative Medicine Institute), Chee Wah Tan(Duke-NUS Medical School)
Cited by 19
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
|Nature Medicine|2020|490
Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers
|The Journal of Experimental Medicine|2015|381